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Abstract: A newly developed series of non-imidazole histamine H3 receptor (H3R) antagonists (1–16)
was evaluated in vivo for anticonvulsant effects in three different seizure models in Wistar rats.
Among the novel H3R antagonists examined, H3R antagonist 4 shortened the duration of tonic hind
limb extension (THLE) in a dose-dependent fashion in the maximal electroshock (MES)-induced
seizure and offered full protection against pentylenetetrazole (PTZ)-induced generalized tonic-clonic
seizure (GTCS), following acute systemic administration (2.5, 5, 10, and 15 mg/kg, i.p.). However,
only H3R antagonist 13, without appreciable protective effects in MES- and PTZ-induced seizure,
fully protected animals in the strychnine (STR)-induced GTCS following acute systemic pretreatment
(10 mg/kg, i.p.). Moreover, the protective effect observed with H3R antagonist 4 in MES-induced
seizure was completely abolished when animals were co-administered with the H3R agonist
(R)-α-methylhistamine (RAMH, 10 mg/kg, i.p.). However, RAMH failed to abolish the full protection
provided by the H3R antagonist 4 in PTZ-induced seizure and H3R antagonist 13 in STR-induced
seizure. Furthermore, in vitro antiproliferative effects or possible metabolic interactions could not be
observed for compound 4. Additionally, the predictive in silico, as well as in vitro, metabolic stability
for the most promising H3R antagonist 4 was assessed. The obtained results show prospective effects
of non-imidazole H3R antagonists as innovative antiepileptic drugs (AEDs) for potential single use
against epilepsy.
Keywords: histamine H3 receptors; antagonists; anticonvulsant; maximal electroshock;
pentylenetetrazole; strychnine; antiproliferative action; metabolic stability
1. Introduction
Epilepsy is considered as a brain disease characterized by repeated seizures due to different
complex causes including idiopathic (ion channel or protein defects), symptomatic stroke, head injury
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(tumors in the brain or central infectious diseases), metabolic disorders (e.g., imbalance of several
electrolytes, uremia, and hyperglycemia), or genetic mutation of DNA sequences in genes responsible
for encoding various ion channels or neurotransmitter receptors [1,2]. In addition, many patients
diagnosed with epilepsy also show cognitive comorbid features, for example, deficiency in intellectual
ability; impaired learning and memory; and behavioral neuropsychiatric disorders, such as depression,
aggression, or problems in social relationships that intensify the costs for their healthcare [3]. Clinically
obtainable antiepileptic drugs (AEDs) still have a large number of non-responders with the clinical
drawback that around 30% of epileptic patients do not respond to current therapies [4,5]. More than
fifteen new AEDs, including lamotrigine, levetiracetam, retigabine, and perampanel, were approved
during the last twenty-five years [6]. However, numerous AEDs cause several unwanted adverse
effects, with the most common ones being behavioral and cognitive deficiencies, weight gain,
coordination problems, dizziness, and gait disturbance [6]. As long life drug treatment is indispensable,
the search for new and more effective AEDs with improved safety profiles is an imperative therapeutic
goal [5]. Therefore, there is still a high therapeutic need for new medical entities.
Preclinical and clinical studies indicated that several brain monoamines such as serotonin,
dopamine, noradrenaline, histamine, or melatonin play a significant role in seizure activity [7,8].
Previous studies have investigated in the brain histamine’s role in seizure pathophysiology [9,10].
Accordingly, histamine itself is considered as an endogenous anticonvulsant [9,11], while histamine H1
receptor (H1R) antagonists were found to prompt or promote seizures [12,13]. Furthermore, preclinical
experiments in several rodents revealed that inhibition of N-methyltransferase, the histamine
metabolizing enzyme in the central nervous system (CNS), using metoprine elevated the levels
of brain histamine and, therefore, reduced seizure susceptibility [14–17]. On the other hand,
α-fluoromethylhistidine (α-FMH, the histamine synthesizing enzyme in the CNS) escalated seizure
activity in experimental animals as a result of inhibition of histidine decarboxylase (HDC), which
minimized the biosynthesis of brain histamine [18].
Histamine acts by four distinct histamine receptor subtypes (H1R–H4R), which belong to class A
of the G-protein coupled receptor family [19]. H1R and H2R are largely found in the CNS and periphery,
H3Rs are abundant in the brain, while H4Rs are chiefly expressed in mast cells and leukocytes [20].
Activation of H1R and H2R stimulates slow excitatory postsynaptic potential, while H3Rs is coupled
to Gi/Go-proteins, which regulate the biosynthesis and release of brain histamine by acting as
auto-receptors [19,21,22]. Moreover, H3Rs operating as hetero-receptors can also modulate the
release of various other brain neurotransmitters in different brain regions, for example, acetylcholine,
glutamate, gamma-aminobutyric acid (GABA), norepinephrine, serotonin, and dopamine [23].
Previous experimental observations from our research [24–30] and that of other research
groups [18,31–34] signified the anticonvulsant activity of several histamine H3R antagonists,
which could be connected to their antagonistic effects on histamine H3Rs. In different rodent models
of seizure, both the imidazole-based H3R antagonist thioperamide [32,35,36] and non-imidazole-based
H3R antagonists [26–29] reduced seizures or displayed full protective effects in the maximal
electroshock (MES)- and pentylenetetrazole (PTZ)-induced seizure models. Pitolisant (PIT), which is
the first H3R antagonist to reach the market (Wakix®; Bioprojet Pharma—as an orphan drug
for the treatment of narcolepsy [37]), also presented effectiveness in different animal models of
epilepsy [25,33,38], which could not be confirmed so far in clinical trials [34] (Table 1).
Based on the aforementioned preclinical and clinical results, the current study examined the
anticonvulsant effects of newly developed N-alkyl-substituted (homo)piperidine ether derivatives
(1–16) (Table 1). These novel H3R antagonists (1–16) were developed as structural modifications
of PIT and comprise different cycloalkylamine functionalities in the basic part of target ligands,
different alkyl chain lengths (five or six methylene groups), as well as variable positions of
methyl at the basic piperidine ring (3-CH3 or 4-CH3) (Table 1). First, their in vitro affinities
on human histamine H3Rs (hH3Rs) were evaluated. Second, their anticonvulsant effects were
examined in the MES-, PTZ-, and strychnine (STR)-induced seizures in male adult rats. The latter
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in vivo seizure test models were selected based on earlier preclinical observations, in which the
anticonvulsant efficacy of numerous imidazole as well as non-imidazole H3R antagonists was
established [39–41]. Third, the ability of the CNS penetrant H3R agonist (R)-α-methylhistamine
(RAMH) to counteract the protection provided by the most promising H3R antagonists was
considered. Fourth, the in vitro selectivity profile towards HRs subtypes for compounds with the
most promising anticonvulsant effects was evaluated on human HRs expressed in different cell lines.
Fifth, the absorption-distribution-metabolism-excretion-Toxicology (ADME-Tox) profile of the H3R
antagonist with the most promising anticonvulsant efficacy was further assessed for antiproliferative
activity, for metabolic stability, and for the potential of drug-drug interaction.
2. Material and Methods
2.1. In Vitro Pharmacology
2.1.1. Human Histamine H3 Receptor (hH3R) Binding Affinity for Tested Compounds 1–16
As described previously [28,42,43], the affinity for the human histamine H3R was tested utilizing
radioligand displacement assays with [3H]Nα-methylhistamine at membrane preparations from
human embryonic kidney (HEK)-293 cells, stably expressing the receptor. Assays ran in triplicates
with seven concentrations of the test compounds 1–16 (Table 1). The analysis of data was conducted
by the software GraphPad Prism 7 (San Diego, CA, USA), using the “one-site competition” equation.
Ki values were calculated from the 50 percent of inhibitory concentration (IC50) values according to the
Cheng-Prusoff equation [44] (Table 1).
Table 1. In vitro human histamine H3 receptor (hH3R) affinities of ligands 1–16.
Ligand Structure In Vitro Affinity Ki (hH3R) a in nM [CI]
1
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2.2. In Viv Pharmac logy
2.2.1. Animals
Inbred male Wistar rats aged between six and eight weeks (body weight: 180–220 g,
Central Animal Facility of the United Arab Emirates (UAE) University, Al Ain/Abu Dhabi, United Arab
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Emirates) were used. Animals were kept in an air-conditioned animal facility room with controlled
temperature (24 ± 1 ◦C) and humidity (55 ± 15%) under a 12-h light/dark cycle. The animals were
allowed free access to food and water. The experiments of the current study were carried out between
09:00 and 12:00, and all procedures were performed according to the guidelines of the European
Communities Council Directive of 24 November 1986 (86/609/European Economic Community
(EEC)) and were previously approved for epilepsy study by the College of Medicine and Health
Sciences/United Arab Emirates University (Institutional Animal Ethics Committee, approval number;
ERA_2017_5676).
2.2.2. Drugs
H3R agonist (R)-α-methylhistamine (RAMH, 10 mg/kg, i.p.), pentylenetetrazole
(PTZ, 60 mg/kg, i.p.), strychnine (STR, 3.5 mg/kg, i.p.), phenytoin (PHT), and valproic
acid (VPA, 300 mg/kg, i.p) were purchased from Sigma-Aldrich (St Louis, MI,
USA). H3R antagonists: (1) 3-methyl-1-(5-(naphthalen-2-yloxy)pentyl)piperidine
hydrogen oxalate [45]; (2) 1-(5-(naphthalen-2-yloxy)pentyl)azepane hydrogen oxalate [45];
(3) 3-methyl-1-(6-(naphthalen-2-yloxy)hexyl)piperidine hydrogen oxalate [45]; (4) 1-(6-(naphthalen-
2-yloxy)hexyl)azepane hydrogen oxalate [45]. All other compounds are unpublished to
best of our knowledge: (5) phenyl(4-(6-(piperidin-1-yl)hexyloxy)phenyl)methanone hydrogen
oxalate; (6) (4-(6-(3-methylpiperidin-1-yl)hexyloxy)phenyl)(phenyl)methanone hydrogen oxalate;
(7) (4-(6-(azepan-1-yl)hexyloxy)phenyl)(phenyl)methanone hydrogen oxalate; (8) phenyl(3-(6-(piperidin-1-
yl)hexyloxy)phenyl)methanone hydrogen oxalate (unpublished); (9) (3-(6-(3-methylpiperidin-1-yl)
hexyloxy)phenyl)(phenyl)methanone hydrogen oxalate; (10) (3-(6-(azepan-1-yl)hexyloxy)phenyl)
(phenyl)methanone hydrogen oxalate; (11) 1-(6-(4-fluorophenoxy)hexyl)piperidine hydrogen oxalate;
(12) 1-(6-(4-fluorophenoxy)hexyl)-3-methylpiperidine hydrogen oxalate; (13)
1-(6-(4-fluorophenoxy)hexyl)azepane hydrogen oxalate; (14) phenyl(4-(5-(piperidin-1-yl)pentyloxy)phenyl)
methanone hydrogen oxalate; (15) (4-(5-(3-methylpiperidin-1-yl)pentyloxy)phenyl)(phenyl)methanone
hydrogen oxalate; and (16) (4-(5-(azepan-1-yl)pentyloxy)phenyl)(phenyl)methanone hydrogen
oxalate. These synthesized by us in the Department of Technology and Biotechnology of Drugs (Kraków,
Poland) (Table 1) according to methods described previously [24,45]. For the in vivo anticonvulsant
screening, test compounds 1–16, PHT, VPA, and RAMH were suspended in 1% aqueous solution of
Tween 80 and administered intraperitoneally (i.p.) at a volume of 1 mL/kg 30–45 min before the test.
Control animals (negative control) were given an appropriate amount of vehicle (1% aqueous solution of
Tween 80; i.p.) 30–45 min before the test. Doses of all test compounds were expressed in terms of the free
base. For each test compound, a group of six to seven animals was used for the anticonvulsant study
(Table 1).
2.2.3. Maximal Electroshock (MES)-Induced Seizure
As previously described [30,46], the seizures were induced in rats with a 50 Hz alternating current
of 120 mA intensity. The current was applied through ear electrodes for 1 s. Protection against the
spread of MES-induced seizure was defined as the abolition of the tonic hind limb extension (THLE)
component of the seizure [25,29,47]. For the first screening of protective effects of test compounds
1–16 in the MES-induced seizure model, the animals were divided into eighteen groups of seven rats
(n = 7) as follows; group (1) control group injected with vehicle (SAL), group (2) positive control group
in which rats were injected with PHT at a dose of 10 mg/kg (this being the minimal dose of PHT
that protected animals against the spread of MES-induced seizures without mortality), and groups
(3)–(18) animals in the experimental groups were administered H3R antagonists 1–16 at a dose of
10 mg/kg. In another MES experiment in three separate groups of six rats (n = 6), H3R antagonist 4
with the most promising protection in MES model was administered at doses of 2.5, 5, or 15 mg/kg,
i.p. 30–45 min before the MES challenge. In an additional abrogative experiment, the most effective
dose of H3R antagonist 4 was designated for further analysis in which a separate group of six rats
Int. J. Mol. Sci. 2018, 19, 3386 6 of 23
(n = 6) was co-injected with the selected dose of H3R antagonist 4 (30–45 min prior to MES test) with
RAMH (10 mg/kg, i.p., 15–20 min before MES challenge) (Figure 1, Table 2).
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Figure 1. Dose-dependent protective effect of hista ine 3 receptor ( 3R) antagonist 4 and effect of
(R)-α- ethylhista ine (RA H) pretreat ent on the H3R antagonist 4 provided protection against
maximal electroshock ( ES)-induced convulsions. The figure shows the protection provided by
standard antiepileptic drug (AED) phenytoin (PHT, 10 mg/kg, i.p.) and test compound 4 (2.5, 5, 10, and
15 mg/kg, i.p.) on the duration of tonic hind limb extension (THLE) induced in the MES model in rats.
Each value represents mean ± standard error of mean (SEM) (n = 6–7). * p < 0.05 vs. sal (saline)-treated
group. ** p < 0.001 vs. (saline)-treated group. # p < 0.05 vs. (2.5 mg)-treated group. $ p < 0.05 vs. (5 mg
or 15 mg)-treated groups.
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2.2.4. Che ically-Indu ed S izures
In this tudy and according to pr viously used protocols, two chemical agents have been used to
induce seizures, namely pe tylen tetrazole (PTZ, 60 mg/kg, i.p.) and strychnine (STR, 3.5 mg/kg,
i.p.) [27,47]. PTZ 60 mg/kg or STR 3.5 mg/kg were administered i.p. to all gro ps of seven rats
(n = 7), that is, ani als p treated w th vehicle or st compounds 1–16. Vehicl , VPA (300 mg/kg,
i.p.), [ 6, 7–49] o test compounds 1–16 (10 mg/kg, i.p.) wer systemically ad inistered 30–45 min
before PTZ (60 mg/k , i.p.) or STR (3.5 mg/kg, i.p.) inj tion, and animals w re dir ctly observed for
any signs of convulsion for a duration of 30 min. The observ scores as well as percent protection
against generalized tonic-clonic seizure (GTCS) were graded and scal d according to th Racine scale
(stage 0, no change in behavior; stage 1, stereotype mouthing, eye blinking, and/or mild facial clonus;
stage 2, head nodding and/or severe facial clonus; stage 3, myoclonic jerk in forelimbs; stage 4, clonic
convulsions in the forelimbs with rearing; stage 5, generalized colonic convulsions associated with loss
of balance [50]) to evaluate the protection provided by the respective test compound against seizures.
The animals were divided into eighteen groups of seven rats (n = 7) and treated as follows.
(1) Control group injected with vehicle + PTZ (SAL group), (2) positive control group in which
rats were injected with VPA (300 mg/kg) + PTZ (VPA group), and animals in the test groups (3)–(18)
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were systemically administered with test compounds 1–16 (10 mg/kg), respectively. An additional
PTZ experiment was conducted using three different groups of seven rats (n = 7), the H3R ligand with
the most promising protection in PTZ model was administered at doses of 2.5, 5, or 15 mg/kg, i.p.
30–45 min before the PTZ challenge. In an additional abrogative PTZ experiment, the most effective
dose of H3R antagonist 4 was selected for further analysis, namely in a separate group of seven rats
(n = 7), the selected dose of 4 was co-injected (30–45 min prior to PTZ test) together with RAMH
(10 mg/kg, i.p., 15–20 min before PTZ challenge) (Figure 2, Table 2). The same experimental procedure
was followed in the STR-induced seizure model applying the reference drug VPA, which was used at a
dose of 300 mg/kg, i.p. (Figure 3, Table 2).
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Figure 2. Anticonvulsant eff ct of H3R antagonist 4 pretreatment on pentylen tetrazole (PTZ)-induced
convulsion i rats. Valproic acid (VPA, 300 mg/kg, i.p.) and test compound 4 (2.5, 5, 10, and 1 mg/kg,
i.p.) were injected 30–45 min before PTZ (60 mg/kg, i.p.) treatments. Values are r presented as the
mean ± SEM (n = 7). * p < 0.05 vs. (saline)-treated group. ** p < 0.001 . (saline)-treated group.
# p < 0.05 vs. (2.5 mg)-treated group. & Full protection.
2.2.5. Statistical Analysis
For statistical comparisons, the software package SPSS 25.0 (IBM Middle East, Dubai, UAE) was
used. All data are expressed as the means ± standard error of mean (SEM). Ki values at the H3R
are given as means with the 95% confidence interval. Following normal distribution assessment, the
anticonvulsant effects observed for H3R antagonists 1–16 in MES-, PTZ-, and STR-induced convulsion
models were analyzed using one-way analysis of variance, followed by the Bonferroni post hoc test for
multiple comparisons. The criterion for statistical significance was set at p < 0.05.
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2.3. ADME-Tox Properties
2.3.1. Antiproliferative Activity
Human embryonic kidney (HEK)-293 cell line (ATCC CRL-1573) was kindly donated by Prof.
Dr. Christa Müller (Pharmaceutical Institute, Ph maceutical Chemistry I, University of Bonn).
Hepato a HepG2 (ATCC HB-8065) cell line was kind y d nated by the Department of Pharmacological
Screening, Jagiellonian University Medical College. The cell cultures’ growth conditions in presence
of H3R antagonist 4 were applied as described before [46,51]. The cells’ viability was assessed after
72 h of incubation with H3R antagonist and the following references: doxorubicin (Sigma-Aldrich)
and carbonyl cyanide 3-chlorophenylhydrazone (CCCP) (Sigma-Aldrich). CellTiter 96® AQueous
non-radioactive cell proliferation assay (MTS) was purchased from Promega® and added to each
well in the volume of 20 µL. The cells were then incubated for 2–5 h. The microplate reader EnSpire
(PerkinElmer Ltd., Waltham, MA, USA) was used to measure the absorbance at 490 nm.
2.3.2. Prediction of In Silico Metabolism
The in silico prediction for s tes of me abolism of H3R antagonist 4 was performed by MetaSite
5.1.1 provided by Molecular Discovery Ltd. (Bor hamwood, Hertfordshir , UK). The most probable
sites of metabolism were predicted during this study by the liver computational model [52] (Figure 5).
2.3.3. Metabolic Stability
Rat liver microsomes (RLMs) purchased form Sigma-Aldrich (St. Louis, MO, USA) were used
for in vitro determination of compound 4’s metabolic stability. The NADPH regeneration system
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was purchased from Promega (Madison, WI, USA). All experiments were performed as described
before [26,45,46]. The reaction mixture was preincubated at 37 ◦C for 5 min, and then the reaction was
started by adding 50 µL of NADPH regeneration system. The reaction was ended after 120 min by the
addition of cold methanol (200 µL). The mixture was then centrifuged at 14,000 rpm for 15 min and the
ultra-performance liquid chromatography–mass spectrometry (UPLC/MS) analysis of the supernatant
was conducted. Ion fragment analyses were also performed for metabolic pathways’ determination.
2.3.4. Metabolic Interactions
The metabolic interactions of H3R antagonist 4 were determined by the luminescent P450-Glo™
3A4 and 2D6 assays purchased from Promega®. All enzymatic reactions were performed according to
the manufacturer protocols and as previously described [26]. The references ketoconazole (KE, CYP3A4
inhibitor) and quinidine (QD, CYP2D6 inhibitor) were obtained from Sigma-Aldrich. The luminescence
was measured with a microplate reader EnSpire (PerkinElmer). The final concentration of H3R
antagonist 4 was in the range of 0.1–25 µM, whereas reference inhibitory effects ranged from 0.01 µM
to 10 µM. The IC50 values’ calculations were performed by GraphPad Prism™ software (version 5.01,
San Diego, CA, USA).
3. Results
3.1. Pharmacology
3.1.1. In Vitro Affinities at hH1Rs, hH3Rs, and hH4Rs
The novel ligands 1–16 were tested for their H3R affinity by [3H]Nα-methylhistamine
displacement assays on membrane preparations of HEK-293 cells, stably expressing the hH3R (Table 1).
Following assessment of in vivo anticonvulsant effects in MES-, PTZ-, and STR-induced seizure models
for H3R antagonists 1–16, only selected H3R antagonists (4, 7, and 13), with the most promising in vivo
anticonvulsant effects, were further evaluated for their affinity at human histamine H1 (hH1R) and
H4 (hH4R) receptors. The results show that test compounds 1–16 had an H3R affinity of 40–140 nM
compared with the standard H3R antagonist PIT with an H3R affinity of 12 nM (Table 1). Selected
test compounds with the most promising in vivo anticonvulsant effects, namely 4 (1273.0 nM for H1R,
69.3 nM for H3R, >10,000 nM for H4R), 7 (915 nM for H1R, 40.5 nM for H3R, >10,000 nM for H4R), and
13 (1338.0 nM for H1R, 137.2 nM for H3R, >10,000 nM for H4R), showed a selectivity profile toward
H3Rs with at least 10-fold lower affinity at hH1- and H4Rs.
3.1.2. In Vivo Seizure Models
With regard to the MES test, the current one used in the study produced seizures in 100% of
animals without mortality. Likewise, the dose of PTZ and STR used in the present study formed
seizures (score 4–5) in 100% of animals without mortality.
Anticonvulsant Screening of H3R Antagonists 1–16 in MES-Induced Seizure
The preliminary screening for anticonvulsant activities of acute systemic pretreatment with H3R
ligands 1–16 on MES-induced seizures in rats was carried out and the observed results were compared
with the protective effect of the reference antiepileptic drug PHT in MES-induced seizure in rats
(Tables 2 and 3). The obtained results showed that acute systemic administration of PHT (10 mg/kg,
i.p.) and H3R ligands 1–16 (10 mg/kg, i.p.) demonstrated a significant protection against MES-induced
seizures as confirmed by one-way analysis of variance [F(17,108) = 8.352; p < 0.001]. Among the H3R
antagonists tested and following post hoc analyses, compound 4 at a dose of 10 mg/kg significantly
exhibited the most promising protective effect in MES-induced seizure when compared with the
saline-treated group with [F(1,12) = 34.608; p < 0.001], and provided comparable protection to that of
PHT with [F(1,12) = 1.135; p < 0.308] (Tables 2 and 3, Figure 1). Moreover, the protection observed
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with H3R antagonist 4 at a dose of 10 mg/kg, i.p. was significantly higher than that found for
H3R antagonists 3, 5, 6, 7, 8, and 14 with [F(1,12) = 5.882; p < 0.05], [F(1,12) = 9.722; p < 0.05], [F(1,12)
= 8.20; p < 0.05], [F(1,12) = 6.030; p < 0.05], [F(1,12) = 11.377; p < 0.05], and [F(1,12) = 7.108; p < 0.05],
respectively (Table S1, Supplementary Material). On the other hand, the results show that animals
pretreated with 2.5, 5, and 15 mg/kg of H3R antagonist 4 were protected to a significantly lesser extent
against seizures when compared with the H3R antagonist 4 (10 mg)-treated group with [F(1,11) = 6.087;
p < 0.05] [F(1,11) = 21.843; p < 0.001], and [F(1,11) = 8.609; p < 0.05], respectively (Figure 1). Moreover, the
abrogation of H3R antagonist 4-provided protection was assessed by systemic co-administration with
CNS penetrant histamine H3R agonist RAMH (10 mg/kg, i.p.). The results showed that co-injection
with CNS penetrant histamine H3R agonist RAMH (10 mg/kg, i.p.) abrogated the H3R antagonist 4
(10 mg)-provided protection with [F(1,10) = 0.711; p = 0.419] for the comparison of saline–saline vs. 4 +
RAMH (Figure 2). Notably, RAMH when administered alone did not affect MES-induced seizures
with [F(1,10) = 0.359; p = 0.563] for saline–saline vs. saline–RAMH (Figure 1).
Anticonvulsant Screening for H3R Antagonists 1–16 in PTZ-Induced Seizures
The protective effects of H3R antagonists 1–16 (10 mg/kg, i.p.) were assessed and compared
with the protection obtained for the reference antiepileptic drug VPA in PTZ-induced seizures in
rats (Tables 2 and 3). The results show that acute systemic pretreatment with VPA (300 mg/kg, i.p.)
and H3R antagonists 1–16 delivered a significant protective action against PTZ-induced seizures as
confirmed by applying one-way analysis of variance [F(17,108) = 23.925; p < 0.001] (Tables 2 and 3).
Pairwise comparison of the provided protective effects observed over 30 min revealed that H3R
antagonists 4, 7, and 11 delivered full protective activities when compared with the saline-treated
group (all p < 0.001) (Tables 2 and 3). Similarly, VPA (300 mg/kg, i.p.) provided full protection when
compared with saline-treated group with [F(1,12) = 653.40; p < 0.001] (Tables 2 and 3). Moreover, analysis
of variance revealed that full protection was provided after acute systemic administration with 10
or 15 mg/kg of H3R antagonist 4 (all p < 0.001) (Figure 2, Tables 2 and 3). However, pretreatment
with 2.5 or 5 mg/kg of H3R antagonist 4 provided significantly lower protection when compared with
that provided with 10 or 15 mg/kg of the same compound (all p < 0.05) (Figure 2, Tables 2 and 3).
Furthermore, Figure 2 shows the reversal of H3R antagonist 4-provided protection when co-injected
with 10 mg/kg of histamine H3R agonist RAMH. The observed results showed that RAMH failed to
reverse the H3R antagonist 4-provided protection in PTZ-induced seizure model with [F(1,12) = 2.40;
p = 0.147] for 6-treated group versus 4 + RAMH-treated group (Figure 2). Importantly, RAMH alone
did not affect seizure score when compared with effects of the saline-treated group with p = 0.232
(Figure 2, Tables 2 and 3 ).
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Table 3. Effects of H3R antagonists 4 and 13 on THLE duration, average score, and percentage of provided protection against generalized tonic-clonic seizure (GTCS)
in MES-, PTZ-, and STR-induced convulsion models.
Group MES
a-Induced Seizure Group PTZ
b-Induced Seizure Group STR
c-Induced Seizure
Average THLE (s) Average Seizure Score % Protectionagainst GTCS Average Seizure Score
% Protection
against GTCS
SAL 8.14 ± 1.17 SAL 4.71 ± 0.16 28.57 SAL 5 0
PHT (10 mg) 0.90 ± 0.19 ** VPA (300 mg) 0.00 ± 0.00 100 VPA (300 mg) 0 100
4 (2.5 mg) 5.83 ± 1.01 * 4 (2.5 mg) 2.29 ± 0.44 * 100 4 (2.5 mg) − −
4 (5 mg) 2.50 ± 1.21 **,# 4 (5 mg) 0.71 ± 0.31 **,# 100 4 (5 mg) − −
4 (10 mg) 0.57 ± 0.21 **,$ 4 (10 mg) 0.00 ± 0.00 & 100 4 (10 mg) 4.57 ± 0.19 28.57
4 (15 mg) 3.67 ± 0.94 **,# 4 (15 mg) 0.00 ± 0.00 & 100 4 (15 mg) − −
4 (10 mg) + RAMH 6.17 ± 0.59 4 (10 mg) + RAMH 0.29 ± 0.16 ** 100 4 (10 mg) + RAMH − −
SAL + RAMH 7.92 ± 0.60 SAL + RAMH 4.29 ± 0.25 14.29 SAL + RAMH − −
13 (2.5 mg) − 13 (2.5 mg) − − 13 (2.5 mg) 4.86 ± 0.13 14.29
13 (5 mg) − 13 (5 mg) − − 13 (5 mg) 3.00 ± 0.31 ** 85.71
13 (10 mg) 6.43 ± 1.14 13 (10 mg) 2.14 ± 0.47 * 85.71 13 (10 mg) 2.00 ± 0.35 ** 100
13 (15 mg) − 13 (15 mg) − − 13 (15 mg) 2.17 ± 0.31 ** 100
13 (10 mg) + RAMH − 13 (10 mg) + RAMH − − 13 (10 mg) + RAMH 2.14 ± 0.35 ** 100
SAL + RAMH − SAL + RAMH − − SAL + RAMH 4.71 ± 0.16 28.57
a 50-Hz alternating current of 120 mA intensity applied through ear electrodes for a duration of 1 s,. b 60 mg/kg, c 3.5 mg/kg. −: not determined. +: means that two compounds were
co-administered to the tested animals. * p < 0.05 vs. (saline)-treated group. ** p < 0.001 vs. (saline)-treated group. # p < 0.05 vs. (2.5 mg)-treated group. $ p < 0.05 vs. (5 mg or 15 mg)-treated
groups. & Full protection. SAL—saline; PHT—phenytoin; VPA—valproic acid; RAHM—(R)-α-methylhistamine.
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Anticonvulsant Screening for H3R Antagonists 1–16 in STR-Induced Seizures
In STR-induced seizure in rats, H3R antagonist 4 with the most promising effect in MES- and
PTZ-induced seizures failed to provide any appreciable protection in STR-induced seizure when
compared with the saline-treated group after 30 min of observation time with [F(1,12) = 4.50; p = 0.055]
(Tables 2 and 3). However, H3R antagonist 13 without protection in MES-induced seizure and with
weak protection in PTZ-induced seizure exhibited a moderate protective effect in STR-induced seizure
when compared with the saline-treated group with [F(1,12) = 63.00; p < 0.001] (Figure 3, Table 3). Notably,
the reference antiepileptic drug VPA (VPA 300 mg/kg, i.p.) showed significant protection when
compared with saline-treated group after 30 min observation time with [F(1,12) = 236.308; p < 0.001]
(Figure 3, Tables 2 and 3). Moreover, the results showed that acute systemic pretreatment with H3R
antagonist 13 at a lower dose (2.5 mg/kg, i.p.) failed to exhibit protection against STR-induced seizures
when compared with the saline-treated group with [F(1,12) = 1.00; p = 0.337] (Figure 3, Tables 2 and 3).
Furthermore, no significant differences in the protection provided by H3R antagonist 13 (10 mg/kg,
i.p.) were observed when 5 or 15 mg/kg of the same compound was administered with [F(1,12) = 2.842;
p = 0.118] [F(1,12) = 0.079; p = 0.784], respectively (Figure 3, Table 3).
3.2. ADME-Tox Properties
3.2.1. Antiproliferative Assay
The effect of H3R antagonist 4 (0.1–100 µM) on proliferation of HEK-293 and hepatoma HepG2 cell
lines was assessed and compared with the reference cytostatic drug doxorubicin (DX) and hepatotoxin
carbonyl cyanide 3-chlorophenylhydrazone (CCCP) (Figure 4A,B). The results showed that H3R
antagonist 4 significantly decreased proliferation of HepG2 cells only at the highest concentration used
(100 µM), however, decline in proliferation of HEK-293 cells was achieved with two doses of the same
compound, namely 10 and 100 µM (p < 0.001) (Figure 4A,B).
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Figure 4. Antiproliferative effects of H3R antagonist 4. (A) Antiproliferative effects of the reference
drug doxorubicin (DX) and H3R antagonist 4 on HEK-293 cell line after 72 h of incubation.
(B) Antiproliferative effects of the reference drug doxorubicin (DX), hepatotoxin carbonyl cyanide
3-chlorophenylhydrazone (CCCP), and H3R antagonist 4 on HepG2 cell line after 72 h of incubation.
DMSO: dimethyl sulfoxide.
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3.2.2. In Silico Metabolic Stability
The computational procedure MetaSite.5.1.1 provided by Molecular Discovery Ltd. indicated
the sixth position of naphthalene moiety as the most probable site of H3R antagonist 4 metabolism
(blue circle marked; Figure 5). Moreover, the azepane moiety was also shown to be susceptible for
metabolic biotransformations (the darker red color of the marked functional group indicates its higher
probability of being involved in the metabolism pathway; Figure 5). The predicted in silico most
probable metabolic routes included hydroxylation at the sixth position of naphthalene or azepane
group followed by the compound’s oxidative degradation of the aliphatic alkyl chain (data not shown).
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Figure 5. Potential sites of etabolis for H3R antagonist 4. The blue circle arks the site involved
in metabolism with the highest probability. Other potential sites are marked with red color; the
darker the color, the higher the probability of involvement in the metabolism pathway (calculated with
MetaSite [53]).
3.2.3. In Vitro Metabolic Stability
The UPLC analysis of the reaction mixture of H3R antagonist 4 incubated for 120 min with rat
liver microsomes (RLMs) showed that ~18% of this compound was converted into four metabolites,
namely M-I–M-IV (Figure 6A). The MS determination of the molecular mass of the main metabolite
M-I (+32 units) and the comparison of the ion fragments analyses of H3R antagonist 4 and metabolite
M-I suggests the double-hydroxylation at the 6-n-hexylazepane moiety as the main metabolic pathway
(Figure 6B). Moreover, the hydroxylation reactions at the naphthalene moiety and at the aliphatic alkyl
chain were also identified (metabolites M-II–M-IV, Figure 6C).
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Figure 6. The metabolic profile of H3R antagonist after incubation of H3R antagonist 4 with rat liver microsomes. The UPLC spectrum obtained two hours post
incubation of H3R antagonist 6 with rat liver microsomes. (A) Around 20% of H3R antagonist 4 was metabolized. (B) Main metabolite MI of H3R antagonist 4 with a
double-hydroxylation identified as the main metabolic route. (C) The mass spectrometry (MS) fragmentation analysis of most probable hydroxylation sites MII–MIV
with rat liver microsomes. Abbreviations: UPLC, ultra-performance liquid chromatography.
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3.2.4. Metabolic Interactions
The results observed in luminescent CYP3A4 P450-Glo™ assay showed no inhibitory effects of
H3R antagonist 4 on CYP3A4 activity at examined concentrations of 0.1–25 µM (Figure 7A). Moreover,
the observed results in luminescent CYP2D6 P450-Glo™ assay revealed that the inhibitory effect of
H3R antagonist 6 was detected with an IC50 value of 0.67 µM (Figure 7B).
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All novel H3R antagonists were evaluated in the form of hydrogen oxalate salts in radioligand 
displacement assays. Tested H3R antagonists 1–16 displayed affinities at the human H3R in a 
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Figure 7. Effect of H3R antagonist 4 on CYP3A4 and CYP2D6 activity. (A) Effects of ketoconazole
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4. Discussion
4.1. In Vitro Histamine H3 Receptor Affinity of Test Compounds 1–16
All novel H3R antagonists were evaluated in the form of hydrogen oxalate salts in radioligand
displacement assays. Tested H3R antagonists 1–16 displayed affinities the hum n H3R in
a nanomolar concentration range (Ki: 36–137 nM, Table 1). Compounds 13–15 displayed Ki values
similar to that of pi olisa t (12 nM, Table ), while the 4-fluorophenyl derivatives were th least potent
ones (11–13; Ki: 83.6–137.2 nM).
4.2. Selectivity of Selected H3R Antagonists towards Other Histamine Receptors (H1 and H4)
4.2.1. Histamine H1 Receptor Affinity
As the two histamine receptors H1R and H3R play a pivotal role in the anticonvulsant activity of
the central histamine [41], selected H3R antagonists (6, 9, and 15) were examined in a binding assay at
the human histamine H1R and showed weak affinities (915 ≤ Ki ≤ 1338 nM), being 10-fold lower than
at the H3R.
4.2.2. Histamine H4 Receptor Affinity
As H3R represents the highest degree of homology with H4R [19], the potential interaction with
this receptor subtype for selected H3R antagonists (4, 7, and 13) was evaluated. The observed results
showed that none of the tested H3R antagonists displayed affinity for hH4R (Ki > 10,000 nM).
4.3. In Vivo Anticonvulsant Activity
The results demonstrated that H3R antagonist 4 exhibited the most promising protection against
MES-induced seizures when animals were administered with 10 mg/kg i.p., and as compared with
the saline-treated group of animals (Tables 2 and 3). However, lower doses (2.5 and 5 mg/kg, i.p.) and
a higher dose (15 mg/kg, i.p.) failed to increase the (10 mg) H3R antagonist 4-provided protection
(Figure 1, Table 3). Accordingly, the observed results show a dose-response relationship of the
protection provided and the presence of a ceiling effect for H3R antagonist 4 in the MES-induced
seizure model achieved with a dose of 10 mg/kg, i.p. (Figure 1, Table 3). Notably, the protective
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effect of H3R antagonist 4 (10 mg/kg, i.p.) was similar to that observed in the group treated with the
reference antiepileptic drug PHT (10 mg/kg, i.p.), and was significantly higher than that observed for
H3R ligands 3, 5, 6, 7, 8, and 14 (Figure 1, Table 1). The latter observations are in agreement with recent
preclinical outcomes that showed a dose-dependent anticonvulsant effect of several H3R antagonists
tested in several animal models of seizures. Also, the present results are in line with earlier observations
for the H3R antagonist PIT in a photosensitivity seizure model in adult patients, and in agreement with
earlier observations for several H3R antagonists tested for their anticonvulsant potential in different
animal models of seizures [25–30,33,40,54]. An additional test in the present study showed that the
protection observed for H3R antagonist 4 was abolished when animals were co-administered with
the CNS penetrant histamine H3R agonist RAMH (10 mg/kg i.p.) (Figure 1, Table 3), proposing
that the provided protective effect of H3R antagonist 4 in the MES-induced seizure model involves,
at least to some extent, H3R blockade provided by H3R antagonist 4. Notably, these observations are
consistent with the earlier preclinical results for numerous imidazole- and non-imidazole-based H3R
antagonists [14,25–30,40,54].
H3Rs are auto-receptors presynaptically positioned on histaminergic neurons with an inhibitory
effect on the biosynthesis and release of histamine [21]. Therefore, blocking H3Rs by selective H3R
antagonists, such as H3R antagonist 4, would escalate neuronal release of brain histamine, providing
the protection in the MES-induced seizure in rats. The latter proposed mechanism underlying the
anticonvulsant effect of H3R antagonist 4 is also in line with previous preclinical observations in animal
seizure models in which high doses of several centrally acting H1R antagonists used as anti-allergic
drugs promoted the development of convulsions of tested animals, indicating the involvement of
H1R antagonism, and consequently, brain histaminergic neurotransmission in the seizure promotion.
Noticeably, similar protective effects of imidazole-based and non-imidazole-based H3R antagonists
were earlier described to be abolished either by H3R agonists or by centrally acting H1R antagonists,
suggesting an interaction of the H3R antagonism-released histamine with postsynaptically located
H1Rs on neurons [14,25–30,53,54].
In the PTZ-induced seizure mode, acute systemic administration of VPA (100 mg/kg, i.p.) as well
as H3R antagonists 4, 7, and 11 (10 mg/kg, i.p.) showed full protection (Figure 2, Table 3). Furthermore,
the anticonvulsant effects observed for H3R antagonist 4 at lower doses (2.5 and 5 mg/kg, i.p.) or
a higher dose (15 mg/kg, i.p.) showed a dose-dependent protection in the PTZ-induced seizure model
(Figure 2, Table 3). However, the protective effect of H3R antagonist 4 (10 mg/kg, i.p.) was not
reversed when rats were pretreated with RAMH (10 mg/kg, i.p.) before PTZ challenge, suggesting
that the protection observed for H3R antagonist 4 in PTZ-induced seizure is not facilitated through
modulation of central histaminergic neurotransmission (Figure 2, Table 3). The latter observation may
be explained with the differences in the triggers or the mechanisms and types of seizures each model
represents (MES is considered as a model of generalized tonic-clonic seizures, whereas PTZ (60 mg/kg,
i.p.) induces generalized myoclonic and/or tonic-clonic seizures) [11,53–55]. The failure of RAMH
to reverse the protections provided by H3R antagonist 4 might be explained with its capability to
reduce the suppression of glutamatergic and GABAergic synaptic transmission through blockade of
H3 heteroreceptor function in CNS, necessitating additional future investigations of whether H3R
antagonist 4 modulated the release of inhibitory neurotransmitters, for example, GABA [56].
In the STR-induced seizure model, the results showed that acute systemic administration of
H3R antagonists 4, 7, and 11 (10 mg/kg, i.p.) failed to exhibit appreciable protection during 30 min
of the time observation, whereas H3R antagonist 13 with moderate protection in PTZ and without
any considerable protection in MES demonstrated reasonable protection following 30 min during
the time observation (Figure 3, Table 3). Moreover, the lower doses (2.5 and 5 mg/kg, i.p.) as
well as the higher dose (15 mg/kg, i.p.) of H3R antagonist 13 failed to exhibit a dose-dependent
protection against STR-induced seizure in rats (Figure 3, Table 3). In resemblance to the observations
in PTZ-induced seizure, an additional experiment showed that the H3R antagonist 13-provided
moderate protection in STR-induced seizure was not reversed when animals were co-injected with
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10 mg/kg i.p. of the CNS penetrant histamine H3R agonist RAMH 30–45 min before STR challenge
(Figure 3, Table 3). These findings in STR-induced seizure further comprehend the present results
for the protective effects of the H3R antagonist 4 in PTZ-induced seizure model, as both models are
considered as chemically-induced seizure models. The latter observations for H3R antagonists 1–16
in the STR-induced seizure model show that the moderate protection provided with H3R antagonist
13 in STR model is also not facilitated through central histaminergic neurotransmission. Notably,
STR is an established competitive antagonist of the inhibitory amino acid glycine. Therefore, the
inability of H3R antagonist 13 to afford a dose-dependent protection against STR-induced seizure
model advocates little or no modulation effect of H3R antagonist 13 on the glycine receptors, because
the mechanisms underlying STR-induced seizures are supposed to be attributed to its blocking activity
on glycine receptors in the brain as well as in the spinal cord [56]. Notably, most marketed AEDs were
not effective in all conducted convulsion models during preclinical drug development. Accordingly,
carbamazepine, oxcarbazepine and PHT were found to be, and are still, highly effective in MES-induced
model in rodents, however, they failed to protect against convulsions in rodents induced by PTZ, STR,
or picrotoxin [57,58]. On the contrary, ethosuximide and tiagabine, which show high protection in
chemically-induced convulsion models in rodents, lack protection in the MES-induced model when
used at nontoxic doses [58]. Nonetheless, the diversity in preclinical activities detected for numerous
AEDs was translated into the clinical utility of PHT, carbamazepine, and oxcarbazepine, but not
ethosuximide or tiagabine, in patients diagnosed with generalized tonic-clonic convulsions.
4.4. ADME-Tox Properties
The most promising H3R antagonist 4 was selected to evaluate its ADME-Tox properties, which
included the determination of the in vitro safety profile by applying eukaryotic cell lines, the in silico
and in vitro determination of the metabolic stability and main metabolic routes, and the in vitro
assessment of potential drug-drug interactions by bioluminescent enzymatic assays.
In order to determine the potential toxicity, the standard colorimetrical MTS test was used.
This test allowed one to follow up the influence of H3R antagonist 4 on the human embryonic
kidney (HEK-293) and hepatoma HepG2 cell lines’ proliferation. The antiproliferative activity of
H3R antagonist 4 differed between both used cell lines. HEK-293 cells were more susceptible for
antiproliferative activity as revealed in the statistically significant decrease of HEK-293 cell line viability
(p < 0.001), which was observed at concentrations of 10 and 100 µM, whereas in the HepG2 cell line,
the antiproliferative effect was achieved only at a concentration of 100 µM (Figure 4A,B). However,
the obtained results for HEK-293 indicated a satisfying safety profile of H3R antagonist 4 in comparison
with the reference DX, which significantly decreased HEK-293 viability at a much lower concentration
(1 µM) (Figure 4A). Moreover, no significant hepatotoxic effect was observed for H3R antagonist 4,
as the reference drug CCCP decreased HEpG2 viability at 10 µM, whereas H3R antagonist 4 only did
so at 100 µM (Figure 4B).
In further in vitro metabolic stability studies, the results observed for H3R antagonist 4 applying
RLMs revealed good metabolic stability of H3R antagonist 4, as only ~18% of the substrate was
metabolized and converted into four different metabolites after 120 min of incubation at 37 ◦C (Figure 6).
Moreover, the in silico data and the MS fragmentation analyses showed one hydroxylation on the
azepane moiety and another hydroxylation on the hexyl chain, followed by oxidative degradation of
the alkyl chain as the main metabolic routes of H3R antagonist 4 (Figure 5).
Furthermore, H3R antagonist 4 did not affect CYP3A4, whereas CYP2D6 was inhibited in a more
pronounced manner. However, this effect was observed with a 67-fold higher IC50 (IC50 = 0.67 µM) as
compared with the reference drug QD with a calculated IC50 value of 0.01 µM (Figure 7).
5. Conclusions
The tested series of H3R antagonists showed in vitro affinity at the hH3R in the nanomolar
range. The most promising H3R antagonist 4 having the 1-(6-(naphthalen-2-yloxy)hexyl)azepane
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pharmacophore exhibited an affinity for hH3R (Ki = 69.3 nM). The in vivo anticonvulsant results
revealed that H3R antagonist 4 exhibited most promising protection following acute systemic
administration in MES- and PTZ-induced seizure models in rats. Moreover, the protection observed
for H3R antagonist 4 in the MES-induced seizure model was fully reversed when rats were pretreated
with the CNS-penetrant H3R agonist RAMH. However, RAMH failed to abrogate the protective effects
observed for H3R antagonist in PTZ- or STR-induced seizure models, indicating that histaminergic
pathways appear to be involved in the provided anticonvulsant efficacy of H3R antagonist 4 in only
the MES-induced seizure model, but additional pharmacological properties of the compounds or their
metabolites cannot be fully excluded. Moreover, ADME-Tox parameters’ screening revealed satisfying
low cytotoxicity, good metabolic stability, as well as no inhibition of CYP3A4 activity and moderate
inhibition of CYP2D6 activity. Therefore, the overall experimental observations provide promising
potential for the novel H3R antagonist 4 to be used as a potential template for further drug design and
synthesis in the search for potent and active in vivo H3R antagonists, for example, as AED drugs with
a high safety profile. Nonetheless, a battery of additional seizure models with different species is still
required to further corroborate the current results observed for H3R antagonist 4, and to strengthen
the translational value of its potential applicability in the therapeutic management of epilepsy.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/19/11/
3386/s1.
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